Assessment of Anti-Migraine Potential of a Novel α-Adrenoceptor Agonist S19014: Effects on Porcine Carotid and Regional Haemodynamics and Human Coronary Artery

Abstract

Taking into account the drawbacks associated with the use of triptans, attempts are being made to explore other avenues for the treatment of migraine. Recently, it has been shown that both α1- and α2-adrenoceptors mediate the constriction of porcine carotid arteriovenous anastomoses, which has effectively served as an experimental model predictive of anti-migraine activity. The present study investigated the effects of a novel α-adrenoceptor agonist S19014 {spiro[(1,3- diazacyclopent-1-ene)-5 : 2′-(4′,5′-dimethylindane)] fumarate} on carotid and systemic haemodynamics in anaesthetized pigs, and on human isolated coronary arteries. Increasing doses of S19014 (1-30 μg/kg, i.v.) produced a dosedependent initial short-lasting vasopressor response and a decrease of total carotid blood flow and conductance. The carotid blood flow and conductance changes were exclusively due to constriction of carotid arteriovenous anastomoses (capillary blood flow increased) and were accompanied by an increase in arterio-jugular venous oxygen saturation difference. Whereas prazosin (100 μg/kg, i.v.) was ineffective, rauwolscine (300 μg/kg, i.v.) attenuated the responses to S19014. The compound did not much affect the distribution of cardiac output to peripheral organs when compared with the vehicle group. Furthermore, S19014 only slightly contracted the human isolated coronary artery and its contractions, contrary to those of sumatriptan, were not increased in blood vessels precontracted with U46619. These results suggest that (i) the systemic and carotid vascular effects of S19014 are mainly mediated by α2-adrenoceptors, and (ii) S19014 could be effective in the treatment of migraine with an improved cardiovascular tolerance.